460 related articles for article (PubMed ID: 17456853)
1. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.
Sugimoto H; Grahovac G; Zeisberg M; Kalluri R
Diabetes; 2007 Jul; 56(7):1825-33. PubMed ID: 17456853
[TBL] [Abstract][Full Text] [Related]
2. Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?
Coughlan MT; Cooper ME; Forbes JM
Ann N Y Acad Sci; 2005 Jun; 1043():750-8. PubMed ID: 16037302
[TBL] [Abstract][Full Text] [Related]
3. From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy.
Miyata T; Yamamoto M; Izuhara Y
Ann N Y Acad Sci; 2005 Jun; 1043():740-9. PubMed ID: 16037301
[TBL] [Abstract][Full Text] [Related]
4. The bone morphogenetic proteins (BMPs). Their role in renal fibrosis and renal function.
Klahr S
J Nephrol; 2003; 16(2):179-85. PubMed ID: 12768064
[TBL] [Abstract][Full Text] [Related]
5. Tubular atrophy, interstitial fibrosis, and inflammation in type 2 diabetic db/db mice. An accelerated model of advanced diabetic nephropathy.
Ninichuk V; Kulkarni O; Clauss S; Anders H-
Eur J Med Res; 2007 Aug; 12(8):351-5. PubMed ID: 17933712
[TBL] [Abstract][Full Text] [Related]
6. Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats.
Boor P; Celec P; Behuliak M; Grancic P; Kebis A; Kukan M; Pronayová N; Liptaj T; Ostendorf T; Sebeková K
Metabolism; 2009 Nov; 58(11):1669-77. PubMed ID: 19608208
[TBL] [Abstract][Full Text] [Related]
7. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.
Tanimoto M; Gohda T; Kaneko S; Hagiwara S; Murakoshi M; Aoki T; Yamada K; Ito T; Matsumoto M; Horikoshi S; Tomino Y
Metabolism; 2007 Feb; 56(2):160-7. PubMed ID: 17224327
[TBL] [Abstract][Full Text] [Related]
8. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models.
Zeisberg M; Bottiglio C; Kumar N; Maeshima Y; Strutz F; Müller GA; Kalluri R
Am J Physiol Renal Physiol; 2003 Dec; 285(6):F1060-7. PubMed ID: 12915382
[TBL] [Abstract][Full Text] [Related]
9. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin.
Myint KM; Yamamoto Y; Doi T; Kato I; Harashima A; Yonekura H; Watanabe T; Shinohara H; Takeuchi M; Tsuneyama K; Hashimoto N; Asano M; Takasawa S; Okamoto H; Yamamoto H
Diabetes; 2006 Sep; 55(9):2510-22. PubMed ID: 16936199
[TBL] [Abstract][Full Text] [Related]
10. The effects of rapamycin in the progression of renal fibrosis.
Damião MJ; Bertocchi AP; Monteiro RM; Gonçalves GM; Cenedeze MA; Feitoza CQ; Marques GD; Giannocco G; Mazzali M; Teixeira VP; Dos Reis MA; Pacheco-Silva A; Câmara NO
Transplant Proc; 2007 Mar; 39(2):457-9. PubMed ID: 17362758
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway.
Thallas-Bonke V; Thorpe SR; Coughlan MT; Fukami K; Yap FY; Sourris KC; Penfold SA; Bach LA; Cooper ME; Forbes JM
Diabetes; 2008 Feb; 57(2):460-9. PubMed ID: 17959934
[TBL] [Abstract][Full Text] [Related]
12. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy.
Jiang T; Wang XX; Scherzer P; Wilson P; Tallman J; Takahashi H; Li J; Iwahashi M; Sutherland E; Arend L; Levi M
Diabetes; 2007 Oct; 56(10):2485-93. PubMed ID: 17660268
[TBL] [Abstract][Full Text] [Related]
13. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.
Lassila M; Seah KK; Allen TJ; Thallas V; Thomas MC; Candido R; Burns WC; Forbes JM; Calkin AC; Cooper ME; Jandeleit-Dahm KA
J Am Soc Nephrol; 2004 Aug; 15(8):2125-38. PubMed ID: 15284298
[TBL] [Abstract][Full Text] [Related]
14. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice.
Yamamoto Y; Kato I; Doi T; Yonekura H; Ohashi S; Takeuchi M; Watanabe T; Yamagishi S; Sakurai S; Takasawa S; Okamoto H; Yamamoto H
J Clin Invest; 2001 Jul; 108(2):261-8. PubMed ID: 11457879
[TBL] [Abstract][Full Text] [Related]
15. Renoprotective effects of the AGE-inhibitor pyridoxamine in experimental chronic allograft nephropathy in rats.
Waanders F; van den Berg E; Nagai R; van Veen I; Navis G; van Goor H
Nephrol Dial Transplant; 2008 Feb; 23(2):518-24. PubMed ID: 17905804
[TBL] [Abstract][Full Text] [Related]
16. Loganin attenuates diabetic nephropathy in C57BL/6J mice with diabetes induced by streptozotocin and fed with diets containing high level of advanced glycation end products.
Liu K; Xu H; Lv G; Liu B; Lee MK; Lu C; Lv X; Wu Y
Life Sci; 2015 Feb; 123():78-85. PubMed ID: 25623853
[TBL] [Abstract][Full Text] [Related]
17. Synergistic contributions of carbonyl stress and megsin in diabetic nephropathy.
Inagi R; Nangaku M; Miyata T
Ann N Y Acad Sci; 2005 Jun; 1043():605-8. PubMed ID: 16037283
[TBL] [Abstract][Full Text] [Related]
18. Adverse renal effects of the AGE inhibitor pyridoxamine in combination with ACEi in non-diabetic adriamycin-induced renal damage in rats.
Waanders F; van Goor H; Navis G
Kidney Blood Press Res; 2008; 31(5):350-9. PubMed ID: 19018148
[TBL] [Abstract][Full Text] [Related]
19. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy.
Wang S; Chen Q; Simon TC; Strebeck F; Chaudhary L; Morrissey J; Liapis H; Klahr S; Hruska KA
Kidney Int; 2003 Jun; 63(6):2037-49. PubMed ID: 12753291
[TBL] [Abstract][Full Text] [Related]
20. Pyridoxamine (BioStratum).
Giannoukakis N
Curr Opin Investig Drugs; 2005 Apr; 6(4):410-8. PubMed ID: 15898348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
